[Skip to Content]
[Skip to Content Landing]
May 2012

Ustekinumab for Pyoderma Gangrenosum

Author Affiliations

Author Affiliations: Institute of Clinical Medicine and University of Helsinki and Department of Dermatology, Allergology, and Venereology, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.

Arch Dermatol. 2012;148(5):655. doi:10.1001/archdermatol.2012.78

I read with great interest the article by Guenova et al,1 who showed a biological “proof of concept” with an increase expression of interleukin (IL)-23 in a pyoderma gangrenosum (PG) lesion before initiating ustekinumab therapy successfully. A wide number of local and systemic treatments have been tried for this difficult condition and, in the era of biological agents, new, targeted therapies are promising.2